glucose, (beta-d)-isomer has been researched along with exenatide in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 11 (45.83) | 2.80 |
| Authors | Studies |
|---|---|
| Grasso, P; Leinung, MC | 1 |
| Kvapil, M | 1 |
| D'Souza, LJ; Janssen, S; Parkes, DG; Polizzi, C; Tatarkiewicz, K; Villescaz, C; Wang, Y | 1 |
| Amini, S; Eriksson, JW; Johnsson, E; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
| Mudher Mikhael, E | 1 |
| Close, KL; Dove, AE; Gao, HX; Marathe, PH; Odeh, SA | 1 |
| Eriksson, JW; Johnsson, E; Katsogiannos, P; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
| Bouwens, L; Martens, GA; Roels, S; Song, I | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Öhman, P | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, S; Öhman, P; Wang, H | 1 |
| Dunham, MW; Hurren, KM | 1 |
| Abdul-Ghani, M; DeFronzo, RA; Fawaz, M; Jayyousi, A; Megahed, A; Migahid, O; Singh, R | 1 |
| Arena, S; Avogaro, A; Berchialla, P; Bottigliengo, D; Buzzetti, R; D'Angelo, P; Fadini, GP; Franzetti, I; Sciannameo, V; Vinci, C | 1 |
| Baldi, S; DeFronzo, RA; Ferrannini, E; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Repetto, E | 1 |
| Ferrannini, E; Gastaldelli, A; Guja, C; Han, J; Hardy, E; Jabbour, SA; Repetto, E | 1 |
| Ahmed, A; Choi, J; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Sjöström, CD | 1 |
| Bastian, M; Brath, H; Harreiter, J; Just, I; Kautzky-Willer, A; Klepochova, R; Krššák, M; Leutner, M; Schelkshorn, C | 1 |
| Bellanger, D; Chappell, N; Elkind-Hirsch, KE; Seidemann, E; Storment, J | 1 |
| Barkhof, F; IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Schrantee, A; van Bloemendaal, L; van Ruiten, CC; Veltman, DJ | 1 |
| Adams, J; Agyin, C; Alatrach, M; Cersosimo, E; DeFronzo, RA; Gastaldelli, A; Lavryneko, O; Solis-Herrera, C; Triplitt, C | 1 |
| Heni, M; Hummel, J; Kullmann, S | 1 |
| IJzerman, RG; Kok, MD; Kramer, MHH; Nieuwdorp, M; Serné, EH; Smits, MM; van Raalte, DH; van Ruiten, CC | 1 |
| IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Ten Kulve, JS; van Ruiten, CC; Veltman, DJ; Wijdeveld, M | 1 |
| IJzerman, RG; Nieuwdorp, M; van Ruiten, CC; Veltman, DJ | 1 |
3 review(s) available for glucose, (beta-d)-isomer and exenatide
| Article | Year |
|---|---|
[New drugs in type 2 diabetes mellitus therapy].
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Peptides; Venoms | 2013 |
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide-1 Receptor; Glucosides; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Peptides; Pyrrolidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Vildagliptin | 2016 |
Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Peptides; Sodium-Glucose Transporter 1; Venoms | 2018 |
14 trial(s) available for glucose, (beta-d)-isomer and exenatide
| Article | Year |
|---|---|
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glucose Intolerance; Glucosides; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Obesity; Peptides; Prediabetic State; Treatment Outcome; Venoms; Weight Loss | 2017 |
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Ghrelin; Glucosides; Humans; Hypoglycemic Agents; Male; Membrane Transport Modulators; Middle Aged; Obesity; Peptides; Prediabetic State; Proof of Concept Study; Risk Factors; Sodium-Glucose Transport Proteins; Sweden; Venoms; Weight Loss | 2017 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Topics: Anti-Obesity Agents; Benzhydryl Compounds; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Middle Aged; Sodium-Glucose Transport Proteins | 2018 |
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Exenatide; Female; Glucosides; Humans; Insulin; Ketones; Male; Middle Aged; Pioglitazone; Qatar; Treatment Outcome | 2019 |
Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucosides; Humans; Hypoglycemic Agents | 2020 |
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Exenatide; Fibrosis; Glucosides; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Prospective Studies | 2020 |
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2020 |
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-contr
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Lipids; Liver Neoplasms; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Phentermine; Polycystic Ovary Syndrome; Prospective Studies; Single-Blind Method; Topiramate; Treatment Outcome; Weight Loss; Young Adult | 2021 |
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Brain; Cues; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Brain; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Obesity; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.
Topics: Benzhydryl Compounds; Brain; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
7 other study(ies) available for glucose, (beta-d)-isomer and exenatide
| Article | Year |
|---|---|
[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Drug Combinations; Drug Synergism; Eating; Energy Metabolism; Exenatide; Glucosides; Hypoglycemic Agents; Insulin; Insulin Resistance; Islet Amyloid Polypeptide; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Peptide Fragments; Peptides; Venoms | 2012 |
Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Exenatide; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Male; Mice; Mice, Inbred NOD; Peptides; Venoms | 2014 |
Diabetes News.
Topics: Benzhydryl Compounds; Congresses as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Peptides; Treatment Outcome; Venoms | 2017 |
Circulating microRNA-375 as biomarker of pancreatic beta cell death and protection of beta cell mass by cytoprotective compounds.
Topics: Animals; Apoptosis; Biomarkers; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Exenatide; Glucosides; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Mice; Mice, Inbred BALB C; MicroRNAs; Pancreas; Peptides; Phenylpropionates; Protective Agents; Streptozocin; Venoms | 2017 |
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2019 |
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glucagon; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
Topics: Benzhydryl Compounds; Brain; Cues; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2022 |